Clinical evaluation of the effects of levocarnitine chloride (LC-80) on exercise tolerance in stable angina pectoris by the serial multistage treadmill exercise testing: a multicenter, doubleblind study.
-
- SOTOBATA Iwao
- Department of Internal Medicine, Fujita-Gakuen University
-
- NODA Shoji
- Department of Internal Medicine, Tokai City Hospital
-
- HAYASHI Hiroshi
- First Department of Internal Medicine, Nagoya University School of Medicine
-
- YOKOTA Mitsuhiro
- Department of Clinical Laboratory, Nagoya Universty Hospital
-
- TSUZUKI Masato
- Department of Internal Medicine, Saiseikai Hospital
-
- TSUZUKI Jitsuki
- Department of Cardiovascular Medicine, Daido Hospital
-
- GOTO Junki
- Department of Cardiovascular Medicine, Chubu Hospital of National Sanatorium
-
- INAGAKI Haruo
- Department of Cardiovascular Medicine, Toyota Hospital
-
- ITO Atsushi
- Department of Caldiology, Shizuoka Saiseikai Sogo Hospital
-
- HIRAYAMA Haruo
- Department of Cardiovascular Medicine, Hamamatsu Medicine Center
-
- KONDO Teruo
- Department of Internal Medicine, Chita City Hospital
-
- KATO Kazushige
- Department of Internal Medicine, Nishio City Hospital
-
- NAKASHIMA Mitsuyoshi
- Department of Clinical Pharmacology, Hamamatsu University, School of Medicine
Bibliographic Information
- Other Title
-
- 労作狭心症患者におけるトレッドミル運動試験の運動耐容能に対する塩化レボカルニチン(LC‐80)の臨床評価
Description
A multicenter, double-blind study was performed in 46 patients with stable effort angina pectoris on maintenance doses of long-acting nitrate in order to evaluate the effect of levocarnitine chloride (LC-80) tablets, containing 200 mg of levocarnitine chloride, on exercise tolerance. Multistage treadmill exercise testing was performed according to the modified Bruce protocol at the pre-treatment period and after 4 and 8 wk of oral daily doses of 1800 mg of LC-80 or placebo therapy.<BR>In the pre-treatment period, there were no significant differences in treadmill exercise duration, time to the onset of angina, pressure-rate product (PRP), and ST deviation between the placebo and LC-80 groups.<BR>The time to the onset of angina was significantly longer after 4 (P<0.05) and 8 wk (P<0.01) of LC-80 therapy than in the pre-treatment period and the increment in the time to the onset of angina was significantly greater (P<0.05) after 8 wk of LC-80 therapy as compared to placebo administration. In-exercise ST segment depression tended to be of lesser magnitude after 8 wk of LC-80 therapy than in the pretreatment period (P<0.1). Resting and in-exercise blood pressure, heart rate, and PRP were unaffected by LC-80.<BR>In conclusion, the results of the present study suggest that LC-80 may improve exercise tolerance in patients with stable effort angina pectoris with no significant effects on the circulatory response to exercise, and the agent may be clinically employed as an adjunct to the conventional anti-anginal agent in the management of ischemic heart disease.
Journal
-
- Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics
-
Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 20 (3), 607-618, 1989
The Japanese Society of Clinical Pharmacology and Therapeutics
- Tweet
Details 詳細情報について
-
- CRID
- 1390001205368281472
-
- NII Article ID
- 130002046434
-
- ISSN
- 18828272
- 03881601
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- Crossref
- CiNii Articles
- OpenAIRE
-
- Abstract License Flag
- Disallowed